ULIHF (United Laboratories International Holdings) Research & Development: $129 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ULIHF United Laboratories International Holdings Ltd ULIHF
80 GF Score
Price $1.24
GF Value $1.43
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is United Laboratories International Holdings Research & Development?

United Laboratories International Holdings ULIHF 80 Research & Development is $129 Mil as of Dec. 2025. GuruFocus rates ULIHF with a GF Score™ of 80/100 and a GF Value™ of $1.43 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. United Laboratories International Holdings's Research & Development for the six months ended in Dec. 2025 was $60 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $129 Mil.

United Laboratories International Holdings  (OTCPK:ULIHF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

United Laboratories International Holdings Research & Development Related Terms

United Laboratories International Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for United Laboratories International Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

United Laboratories International Holdings Research & Development Chart

United Laboratories International Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 73.05 85.14 106.05 122.35 130.77

United Laboratories International Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58.62 61.59 60.98 69.49 59.93
ULIHF
80GF Score
United Laboratories International Holdings Ltd ULIHF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

United Laboratories International Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $129 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $129 Mil mean?
United Laboratories International Holdings (ULIHF) has a Research & Development of $129 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on United Laboratories International Holdings and its competitors.
Is United Laboratories International Holdings' Research & Development too high?
United Laboratories International Holdings' current Research & Development is $129 Mil. Overall, United Laboratories International Holdings has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does United Laboratories International Holdings' Research & Development compare to ZTS and UTHR?
United Laboratories International Holdings' Research & Development of $129 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on United Laboratories International Holdings and its competitors. United Laboratories International Holdings's current Research & Development is $129 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Laboratories International Holdings stock overvalued right now?
Based on GuruFocus' analysis, United Laboratories International Holdings (ULIHF) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.43, compared to a current price of $1.24 — trading 13.3% below its estimated fair value. The current Research & Development is $129 Mil. United Laboratories International Holdings' overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For United Laboratories International Holdings (ULIHF), the current Research & Development is $129 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is United Laboratories International Holdings (ULIHF) Overvalued in 2026?

Based on GuruFocus' analysis, United Laboratories International Holdings stock appears to be undervalued. The current stock price of $1.24 is trading 13.3% below its estimated GF Value™ of $1.43. GuruFocus considers United Laboratories International Holdings to be Modestly Undervalued.

Key valuation signals for ULIHF:

  • Research & Development: $129 Mil
  • GF Value™: $1.43 vs. price of $1.24 (13.3% below fair value)
  • GF Score™: 80/100 with 5 warning signs

No single metric tells the full story. See the ULIHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

United Laboratories International Holdings Business Description

Other Exchanges 03933:Hong KongUNJ:Germany
Address No. 6 Fuk Wang Street, Yuen Long Industrial Estate, New Territories, Hong Kong, HKG
United Laboratories International Holdings Ltd is mainly engaged in the research and development, production and sales of pharmaceuticals. The company operates in three segments: Intermediate products, Bulk medicine, and Finished products. The company's Finished products segment includes antibiotic products, insulin series products, and other medicines. The vast majority of the company's revenue is derived from its Finished products segment, followed by Bulk medicine. The majority of the company's sales are generated in China, followed by Europe, India and other countries.
80GF Score

Get the complete analysis for ULIHF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.24
Price
$1.43
GF Value